Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells define commitment to apoptosis
暂无分享,去创建一个
B. Druker | M. Deininger | A. Agarwal | J. Tyner | D. Koop | H. You | T. O'hare | K. Vogel | C. Eide | M. Zabriskie | Bryan D. Marks | S. Riddle | D. Latocha | J. Apgar | Kara Johnson | Lauren T. Adrian | Ryan J. Mackenzie | Jenny Luo | Steven M. Riddle | Dorian H Latocha | Ryan J Mackenzie
[1] I. Flinn,et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. , 2012, The New England journal of medicine.
[2] M. Deininger,et al. Pushing the limits of targeted therapy in chronic myeloid leukaemia , 2012, Nature Reviews Cancer.
[3] B. Druker,et al. Cryptic Intracellular Retention of ABL Tyrosine Kinase Inhibitors within CML Cells Mediates Apoptosis Commitment Following Acute Drug Exposure , 2011 .
[4] T. Clackson,et al. ATP Dependent Efflux Transporters ABCB1 and ABCG2 Are Unlikely to Impact the Efficacy, or Mediate Resistance to the Tyrosine Kinase Inhibitor, Ponatinib , 2011 .
[5] Xi-shan Wang,et al. Novel irreversible EGFR tyrosine kinase inhibitor 324674 sensitizes human colon carcinoma HT29 and SW480 cells to apoptosis by blocking the EGFR pathway. , 2011, Biochemical and biophysical research communications.
[6] B. Druker,et al. The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. , 2011, Cancer research.
[7] L. Stewart,et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. , 2011, Cancer cell.
[8] S. Bates,et al. Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib , 2010, Drug Metabolism and Disposition.
[9] J. Melo,et al. Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy , 2010, Leukemia.
[10] T. Clackson,et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. , 2009, Cancer cell.
[11] M. Pirmohamed,et al. Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters , 2009, Leukemia.
[12] R. Koch,et al. ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug , 2009, Haematologica.
[13] G. Szakács,et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti‐cancer effects and pharmacological properties , 2009, British journal of pharmacology.
[14] K. Zaman,et al. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[15] U. Singh,et al. Development and Applications of a Broad-Coverage, TR-FRET-Based Kinase Binding Assay Platform , 2009, Journal of biomolecular screening.
[16] J. Melo,et al. Short-term intense Bcr–Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL+ cells , 2009, Leukemia.
[17] B. Druker,et al. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. , 2007, Blood.
[18] Christopher Weier,et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. , 2008, Cancer cell.
[19] M. Pirmohamed,et al. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. , 2008, Blood.
[20] Andreas Hochhaus,et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Wolfgang Jahnke,et al. Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and Dasatinib*♦ , 2008, Journal of Biological Chemistry.
[22] J. Melo,et al. Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.
[23] P. Erben,et al. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib , 2008, Haematologica.
[24] Tillmann Krahnke,et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. , 2008, Blood.
[25] R. Pazdur,et al. Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate , 2008, Clinical Cancer Research.
[26] G. Superti-Furga,et al. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib , 2008, Leukemia & lymphoma.
[27] Zheng Yang,et al. Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure , 2006, Clinical Cancer Research.
[28] D. Haber,et al. A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. , 2006, Cancer cell.
[29] R. Copeland,et al. Drug–target residence time and its implications for lead optimization , 2006, Nature Reviews Drug Discovery.
[30] M. Fischbach,et al. “Oncogenic Shock”: Explaining Oncogene Addiction through Differential Signal Attenuation , 2006, Clinical Cancer Research.
[31] P. Manley,et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. , 2006, Blood.
[32] K. Bhalla,et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.
[33] E. Scholar,et al. Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.
[34] J. Mestan,et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.
[35] Donna Neuberg,et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.
[36] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[37] D. Hedley,et al. Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell‐based measure of Bcr/Abl kinase activity , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[38] G. Superti-Furga,et al. Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.
[39] A. Pendergast,et al. Activated c-Abl is degraded by the ubiquitin-dependent proteasome pathway , 2001, Current Biology.
[40] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[41] P. Seeburg,et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.
[42] E. Buchdunger,et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. , 1999, Journal of the National Cancer Institute.